With the failure of AbbVie’s emraclidine in two mid-stage trials, Bristol Myers Squibb’s Cobenfy is 'sole muscarinic winner.' ...
Insurer access challenges likely lie ahead for the novel schizophrenia drug Cobenfy, given its considerably higher price than ...
AbbVie stock drops after emraclidine fails Phase 2 trials for schizophrenia, raising questions about its neuroscience ...
AbbVie Inc.’s disappointing trial results for its new schizophrenia drug bode well for rival Bristol Myers Squibb Co., ...
Leerink upgrades Bristol-Myers Squibb with an increased price target and strong sales projections for Cobenfy and milvexian, ...
The U.S. Food and Drug Administration has approved Bristol Myers Squibb's Cobenfy (xanomeline and trospium chloride), a first-in-class muscarinic agonist, for the treatment of schizophrenia in adults.
BMS got its hands on KarXT through its $14 billion buyout of Karuna Therapeutics last December. According to analysts at William Blair, Cobenfy in the U.S. could achieve sales of roughly $2 ...
The FDA approved KarXT for schizophrenia in September. The drug will be marketed for that condition by Bristol Myers (BMY) under the brand name Cobenfy. More on Bristol-Myers Squibb Company , Zai ...
We are encouraged by the progress with the company’s high-quality portfolio, especially the approval of Bristol’s schizophrenia drug Cobenfy (formerly known as KarXT). We view Royalty Pharma ...
Leerink Partners raised its target for Bristol-Myers Squibb from $55 to $73, citing optimism for the company's products Cobenfy (KarXT) and milvexian, a novel blood thinner. Similarly, BMO Capital ...
The drug, previously called KarXT, is an oral medication for the treatment of schizophrenia in adults. Cobenfy introduces a fundamentally new approach to treating schizophrenia by selectively ...